Author

Toshiya Funatsuki

Observed name: T. Funatsuki

Institution: Kansai Medical University

Observed institution: Kansai Medical University

ORCID: 0009-0007-3700-2690

Observed ORCID: 0009-0007-3700-2690

OpenAlex ID: A5066270216

Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis

2023 · Toshiya Funatsuki, Haruhiko Ogata, et al. · International Journal of Molecular Sciences · 25

Effectiveness and Changes in Brain Functions by an Occupational Therapy Program Incorporating Mindfulness in Outpatients with Anxiety and Depression: A Randomized Controlled Trial

2023 · Atsuko Yamamoto, Banri Tsukuda, et al. · Neuropsychobiology · 9

Divergence of dose–response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study

2021 · Yoshiteru Takekita, Shuichi Hiraoka, et al. · CNS Spectrums · 7

C reactive protein albumin ratio as a new predictor of postoperative delirium after cholecystectomy for acute cholecystitis

2024 · Richi Nakatake, Toshiya Funatsuki, et al. · Scientific Reports · 4

Psychometrics of BE ‐ PSD ‐ V2 .0 and its correspondence with PANSS and CGI ‐S

2026 · Hiroyoshi Takeuchi, Naoki Hashimoto, et al. · Psychiatry and Clinical Neurosciences · 3

Frequency of postoperative delirium and associated factors among consultation-liaison psychiatry patients with schizophrenia spectrum disorders undergoing surgery: a retrospective cohort study

2026 · Yoshihiro Matsumoto, Nobutaka Ayani, et al. · Scientific Reports · 1

Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real‐world data

2023 · Yoshiteru Takekita, Shuichi Hiraoka, et al. · Neuropsychopharmacology Reports · 1

Brexpiprazole augmentation of aripiprazole once-monthly in schizophrenia spectrum disorders: A 12-week, open-label, randomised controlled pilot trial (BREATH-JS study)

2026 · Yoshiteru Takekita, Chikashi Takano, et al. · Therapeutic Advances in Psychopharmacology

Treatment strategies of palliative care and psycho-oncology specialists for patients with both pain and delirium: a nationwide survey

2026 · Toshiya Funatsuki, Keita Tagami, et al. · Scientific Reports

A Predictive Scoring Model for Perioperative Psychiatric Symptom Exacerbation in Schizophrenia Spectrum Disorders: Development and Internal Validation

2026 · Yoshihiro Matsumoto, Nobutaka Ayani, et al. · Journal of the Academy of Consultation-Liaison Psychiatry

Association of baseline plasma NMDA receptor–related amino acid ratios with remission following antidepressant treatment in major depressive disorder

2026 · Yuji Murase, Haruhiko Ogata, et al. · Journal of Affective Disorders

W38. Genome-wide Association Study (gwas) of Susceptibility for Major Depressive Disorder in Japanese Population

2025 · Yutaro Shimamoto, Yoshiki Yasukochi, et al. · European Neuropsychopharmacology

T37. Genome-wide Association Study (gwas) of Antidepressant Treatment Response in Major Depressive Disorder in Japanese Population

2025 · Yutaro Shimamoto, Yoshiki Yasukochi, et al. · European Neuropsychopharmacology

Predictors of continuation for asenapine from real-world data in patients with schizophrenia

2024 · Yoshiteru Takekita, Shuichi Hiraoka, et al. · Annals of General Psychiatry

Relationship between treatment response to antidepressants and blood N-methyl-D-aspartate (NMDA) receptor-related amino acids in depressed patients

2024 · Y. Murase, H. Ogata, et al. · Neuroscience Applied

Works count: 15

Citation count: 50

H-index: 4

I10-index: 1